Antibody-mediated Rejection Clinical Trial
Official title:
A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients
This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02533596 -
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
|
N/A | |
Completed |
NCT04367610 -
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
|
||
Completed |
NCT05021484 -
Felzartamab in Late Antibody-Mediated Rejection
|
Phase 2 | |
Terminated |
NCT02120482 -
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
|
N/A | |
Terminated |
NCT03744910 -
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
|
Phase 3 | |
Terminated |
NCT01895127 -
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
|
Phase 2 | |
Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
Recruiting |
NCT03737136 -
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
|
N/A | |
Recruiting |
NCT05913596 -
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
|
N/A | |
Active, not recruiting |
NCT04541914 -
Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT
|
N/A | |
Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
Recruiting |
NCT06112951 -
A Prospective Randomized Trial of ECP in Subclinical AMR
|
N/A | |
Active, not recruiting |
NCT04897438 -
Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection
|
N/A | |
Recruiting |
NCT05004493 -
Biorepository and Registry for Plasma Exchange Patients
|
||
Completed |
NCT04026087 -
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
|
||
Active, not recruiting |
NCT03994783 -
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
|
Phase 3 | |
Not yet recruiting |
NCT05862766 -
Isatuximab in Lung Transplant Recipients
|
Early Phase 1 | |
Recruiting |
NCT04368962 -
DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
|
||
Completed |
NCT03444103 -
A Pilot Trial of Clazakizumab in Late ABMR
|
Phase 2 | |
Recruiting |
NCT05140018 -
Incidence, Course and Outcome of ABMR in Kidney Transplantation
|